Doxycycline: the universal treatment for anogenital chlamydia

Affiliations

¹ Melbourne Sexual Health Centre, Alfred Health, Melbourne 3053, VIC, Australia; Central Clinical School, Monash University, Melbourne, VIC, Australia. Electronic address: christopher.fairley@monash.edu.
² Melbourne Sexual Health Centre, Alfred Health, Melbourne 3053, VIC, Australia; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, VIC, Australia.

Comment

Christopher K Fairley et al. Lancet Infect Dis. 2022 Aug.

. 2022 Aug;22(8):1102-1103.

doi: 10.1016/S1473-3099(22)00173-6. Epub 2022 May 9.

¹ Melbourne Sexual Health Centre, Alfred Health, Melbourne 3053, VIC, Australia; Central Clinical School, Monash University, Melbourne, VIC, Australia. Electronic address: christopher.fairley@monash.edu.
² Melbourne Sexual Health Centre, Alfred Health, Melbourne 3053, VIC, Australia; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, VIC, Australia.

No abstract available

Conflict of interest statement

We declare no competing interests.

Doxycycline versus azithromycin for the treatment of anorectal Chlamydia trachomatis infection in women concurrent with vaginal infection (CHLAZIDOXY study): a multicentre, open-label, randomised, controlled, superiority trial.
Peuchant O, Lhomme E, Martinet P, Grob A, Baïta D, Bernier C, Gibaud SA, Le Hen I, Le Naour E, Trignol-Viguier N, Lanotte P, Lefebvre P, Vachée A, Girard T, Loubinoux J, Bébéar C, Ghezzoul B, Roussillon C, Kret M, de Barbeyrac B; CHLAZIDOXY Study Group. Peuchant O, et al. Lancet Infect Dis. 2022 Aug;22(8):1221-1230. doi: 10.1016/S1473-3099(22)00148-7. Epub 2022 May 9. Lancet Infect Dis. 2022. PMID: 35550262 Clinical Trial.